CHMP Recommends Variation To Pegasys MA

On March 20 2014, the EMA's CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation (MA) for Roche's Pegasys (peginterferon alpha-2a).

The CHMP adopted a change to an indication as follows: ' Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C in patients with compensated liver disease.

This article is tagged to:
Related sectors of this article: Pharmaceuticals & Healthcare, Regulatory - Pharmaceuticals & Healthcare, Anti-infectives, Gastrointestinal
Geography: Europe, Switzerland

Access all of our latest analysis, data and forecasts - request a trial